Insulet (PODD) Set to Announce Quarterly Earnings on Thursday

Insulet (NASDAQ:PODD) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Insulet to post earnings of $0.78 per share for the quarter. Insulet has set its Q3 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The company had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company’s revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.38 earnings per share. On average, analysts expect Insulet to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Insulet Stock Up 0.8 %

Shares of PODD opened at $237.44 on Tuesday. The firm has a market capitalization of $16.65 billion, a price-to-earnings ratio of 43.17, a PEG ratio of 4.32 and a beta of 1.22. Insulet has a 52 week low of $151.56 and a 52 week high of $243.98. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. The business’s fifty day moving average price is $227.10 and its two-hundred day moving average price is $201.65.

Analysts Set New Price Targets

A number of research firms have recently commented on PODD. UBS Group raised their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Piper Sandler boosted their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. BTIG Research upped their price target on Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Raymond James raised their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, Canaccord Genuity Group boosted their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $242.29.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.